文献速递烧伤

乌司他丁对急性烧伤患者结局的影响

Impact of Ulinastatin on Outcomes in Acute Burns Patients.
PubMed 文献 · J Burn Care Res · 2018-01-01

该回顾性比较病例笔记分析纳入孟买Masina医院2012年10月至2015年4月收治的97例急性烧伤患者,其中48例接受乌司他丁(10万IU,每8-12小时一次,平均8.8天)加标准治疗,49例为对照组。乌司他丁组院内死亡率60.4%,低于对照组75.5%;乌司他丁组平均住院时间更长。

要点

  • 乌司他丁可能降低急性烧伤患者死亡率,尤其在烧伤面积40-80%者。
  • 乌司他丁组平均住院时间更长,可能反映死亡延迟。

核心结论

  • 乌司他丁似乎可降低急性烧伤患者死亡率,尤其对烧伤体表面积40-80%的中度范围患者。
  • 乌司他丁似乎可延迟最终死于烧伤损伤患者的死亡时间。

研究设计与样本

  • 回顾性比较病例笔记审查分析,纳入孟买Masina医院2012年10月至2015年4月收治的急性烧伤患者。
  • 共97例患者,乌司他丁组48例,对照组49例。

主要发现

  • 乌司他丁组院内死亡率为60.4%,对照组为75.5%。
  • 乌司他丁组平均住院时间高于对照组,而较短住院时间通常与死亡相关。

关键数值与推荐

  • 乌司他丁用法为100,000 IU,每8至12小时一次,基于临床判断,平均使用8.8天,并加标准医院治疗。

临床怎么用

  • 对于急性烧伤患者,尤其烧伤体表面积40-80%者,可考虑在标准治疗基础上加用乌司他丁以降低死亡率。
  • 使用乌司他丁时需注意住院时间可能延长,可能反映死亡延迟。

局限性

  • 回顾性比较病例笔记审查分析,可能存在选择偏倚和信息偏倚。
  • 乌司他丁使用基于临床判断,非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burns is a global health problem with significant morbidity and mortality. Ulinastatin, a serine protease inhibitor, has the potential to improve outcomes in burns. A retrospective comparative case note review analysis was performed to assess the impact of ulinastatin on the outcomes in acute burns patients. Acute burns patients, admitted to Masina hospital, Mumbai, from October 2012 to April 2015, who received ulinastatin, were identified from the hospital records. A similarly sized cohort of patients, admitted before the introduction of ulinastatin, was also identified. Relevant data were obtained from archived patient files. The outcomes, mortality and length of hospital stay, were compared across different groups and subgroups. Data of 97 patients, 48 of whom received ulinastatin (ulinastatin group) and 49 of whom did not (control group), were captured. Patients in ulinastatin group had received ulinastatin 100,000 IU, 8 to 12 hourly, during a mean period of 8.8 days, based on clinical judgment, in addition to standard hospital care. The in-hospital mortality was lower (60.4%) in ulinastatin group compared with control group (75.5%). The difference in mortality was statistically significant (50% vs 77.27%; P = .04) in those with 41 to 80% burnt BSA. Mean length of hospital stay, where shorter duration of hospitalization is usually associated with death, was higher in ulinastatin group compared with the control group. Ulinastatin appears to reduce mortality in acute burns patients, especially in those with intermediate extent (40 to 80%) of burnt BSA. It also appears to delay death in those who ultimately succumbed to their burn injuries.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Abhyankar SV, Vartak AM. Impact of Ulinastatin on Outcomes in Acute Burns Patients. J Burn Care Res. 2018. PMID: 28394881. doi:10.1097/BCR.0000000000000546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。